MediWound Email Format

Pharmaceutical ManufacturingCentral District, Israel51-200 Employees

MediWound Ltd. is a global biotechnology company in the pharmaceutical manufacturing sector that develops and commercializes enzymatic therapies for non-surgical tissue repair. The company is headquartered at 42 Hayarkon Ben Zakkay, Central District, Israel, and has 51-200 employees; it is listed on NASDAQ under the ticker MDWD. Its FDA-approved biologic NexoBrid is indicated for enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan and other international markets. MediWound is advancing EscharEx, a late-stage investigational therapy for debridement of chronic wounds, which has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market. The company reports revenue in the range of $10 million to $25 million and has received funding; its EscharEx Phase III VALUE trial is advancing with interim assessment and enrollment completion expected by the end of Q1 2027.

Sign up for free to view info

Company overview Employee directory